Minimal residual disease (MRD) is the net result of the biological properties of disseminated tumour cells and the effect of the immune system and treatment to eliminate them. The aim of this work is to report the changes in MRD status and immune function (lymphocyte count) after FOLFOX chemotherapy, and the outcome in Stage III colon cancer patients.

中文翻译：

---

III 期结肠癌 FOLFOX 化疗后免疫功能障碍的改善与微小残留病预后亚型和结果的改善相关

微小残留病（MRD）是播散性肿瘤细胞的生物学特性以及免疫系统和消除它们的治疗作用的最终结果。这项工作的目的是报告 FOLFOX 化疗后 MRD 状态和免疫功能（淋巴细胞计数）的变化，以及 III 期结肠癌患者的结果。